Department of Ophthalmology, Shaare Zedek Medical Center, Jerusalem, Israel, affiliated to the Hebrew University, Jerusalem, Israel.
Department of Ophthalmology, Shaare Zedek Medical Center, Jerusalem, Israel, affiliated to the Hebrew University, Jerusalem, Israel.
J Fr Ophtalmol. 2023 May;46(5):527-535. doi: 10.1016/j.jfo.2022.11.015. Epub 2023 Mar 14.
To assess the impact of lens status on macular function among patients treated for neovascular age-related macular degeneration (nvAMD) in whom scheduled intravitreal injections were delayed.
We reviewed demographic and clinical data as well as macular optical coherence tomographic images of 34 patients (48 eyes) who did not follow their injection schedule during the first wave of COVID-19 in Israel. Functional worsening was defined as a loss of at least 0.1 in decimal best-corrected visual acuity (BCVA). Morphological worsening was defined as new or increased subretinal/intraretinal fluid or a new hemorrhage. OCT indices of quality were used as a measure for cataract density and progression.
Pseudophakia was associated with a better functional outcome than phakic status: there was a loss of 0.06±0.12 vs. 0.15±0.10 decimal BCVA in the pseudophakic and phakic eyes, respectively (P=.001). A similar trend was observed for morphological changes over the same period: there was an increase in macular thickness of 9±26% vs.12±40%, respectively (P=0.79). During the first wave of COVID-19, the index of OCT quality remained stable for phakic eyes (26±3.6 before the first wave of COVID-19, 26±2.9 afterward; P=1) and pseudophakic eyes (30±2.4 before the first wave of COVID-19, 30±2.6 afterward; P=1).
Pseudophakic eyes with nvAMD that missed their scheduled intravitreal injections experienced fewer morphological and functional complications than phakic eyes with nvAMD.
评估在 scheduled intravitreal injections 被延迟的 nvAMD 患者中,晶状体状态对黄斑功能的影响。
我们回顾了 34 名患者(48 只眼)的人口统计学和临床数据以及黄斑光学相干断层扫描图像,这些患者在以色列 COVID-19 第一波期间未能按照注射计划进行治疗。功能恶化定义为十进制最佳矫正视力(BCVA)至少损失 0.1。形态恶化定义为新出现或增加的视网膜下/视网膜内液或新出血。OCT 质量指数被用作衡量白内障密度和进展的指标。
无晶状体眼与有晶状体眼相比,功能结果更好:无晶状体眼的 BCVA 损失为 0.06±0.12,而有晶状体眼的 BCVA 损失为 0.15±0.10(P=.001)。在同一时期,形态变化也呈现出类似的趋势:黄斑厚度分别增加了 9±26%和 12±40%(P=0.79)。在 COVID-19 第一波期间,有晶状体眼的 OCT 质量指数保持稳定(第一波 COVID-19 前为 26±3.6,之后为 26±2.9;P=1)和无晶状体眼(第一波 COVID-19 前为 30±2.4,之后为 30±2.6;P=1)。
错过 scheduled intravitreal injections 的 nvAMD 无晶状体眼比 nvAMD 有晶状体眼经历的形态和功能并发症更少。